)
)
)
iVIEW Therapeutics
iView Therapeutics is a clinical-stage Ophthalmology focused biotechnology company based in Cranbury, New Jersey. Lead assets cover Dry eye, Infectious Conjunctivitis, Myopia, and Glaucoma gene therapy. The lead program, a novel TRPM8 agonist, IVW-1001 Eyelid wipe has achieved statistically significant improvement in key sign and symptom of dry eye patients, including corneal fluorescein staining and SANDE scores, in the phase 2 clinical trials conducted in the US. iView is advancing to pivotal phase 3 clinical trials in early 2026. IVIEW-1201D, a novel sustain release in-situ gel forming composition containing a broad spectrum antiseptic, povidone iodine, and a potent corticosteroid, are moving ahead into phase 3 clinical development for viral conjunctivitis, with phase 3 IND cleared by FDA recently. iView Therapeutics is interested in out-licensing, co-development for phase 3 trials and commercialization, and investment for B round financing.
Address
CranburyNew Jersey
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)